| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2023 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 11/14/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 08/09/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 06/26/2023 | 3.09% | Wedbush | $3 → $2 | Downgrades | Outperform → Neutral |
| 05/31/2023 | 415.46% | Roth MKM | → $10 | Initiates Coverage On | → Buy |
| 05/26/2023 | 209.28% | Citigroup | $5 → $6 | Maintains | Buy |
| 05/10/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 04/25/2023 | 54.64% | Wedbush | $5 → $3 | Maintains | Outperform |
| 03/28/2023 | 209.28% | Mizuho | $12 → $6 | Maintains | Buy |
| 03/28/2023 | 157.73% | Wedbush | $35 → $5 | Maintains | Outperform |
| 03/28/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 03/28/2023 | 157.73% | Citigroup | $15 → $5 | Maintains | Buy |
| 03/16/2023 | 1704.12% | Wedbush | → $35 | Reiterates | → Outperform |
| 03/16/2023 | 415.46% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 02/15/2023 | 415.46% | HC Wainwright & Co. | → $10 | Maintains | Buy |
| 11/16/2022 | 518.56% | Mizuho | $80 → $12 | Maintains | Buy |
| 11/09/2022 | 415.46% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 11/02/2022 | 1755.67% | Wedbush | $4 → $36 | Maintains | Outperform |
| 08/16/2022 | 312.37% | Mizuho | $7 → $8 | Maintains | Buy |
| 08/15/2022 | 312.37% | Citigroup | $5 → $8 | Maintains | Buy |
| 05/17/2022 | 157.73% | Citigroup | $6 → $5 | Maintains | Buy |
| 01/04/2022 | 106.19% | Roth Capital | → $4 | Upgrades | Neutral → Buy |
| 11/10/2021 | 260.82% | Mizuho | $5 → $7 | Upgrades | Neutral → Buy |
| 06/28/2021 | — | Citigroup | Upgrades | Sell → Buy | |
| 06/07/2021 | 518.56% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 08/18/2020 | 157.73% | Morgan Stanley | → $5 | Downgrades | Overweight → Equal-Weight |
| 08/18/2020 | — | Mizuho | Downgrades | Buy → Neutral | |
| 08/18/2020 | 157.73% | Citigroup | $31 → $5 | Downgrades | Buy → Neutral |
| 08/17/2020 | 106.19% | Roth Capital | $35 → $4 | Downgrades | Buy → Neutral |
| 07/28/2020 | 1704.12% | Roth Capital | → $35 | Initiates Coverage On | → Buy |
| 04/15/2020 | 570.1% | Morgan Stanley | $14 → $13 | Maintains | Overweight |
| 12/12/2019 | 930.93% | Cantor Fitzgerald | → $20 | Assumes | → Overweight |
| 03/07/2019 | 982.47% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 12/19/2018 | 1137.11% | Morgan Stanley | $25 → $24 | Maintains | Overweight |
What is the target price for Unity Biotechnology (UBX)?
The latest price target for Unity Biotechnology (NASDAQ: UBX) was reported by Wedbush on November 16, 2023. The analyst firm set a price target for $0.00 expecting UBX to fall to within 12 months (a possible -100.00% downside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Unity Biotechnology (UBX)?
The latest analyst rating for Unity Biotechnology (NASDAQ: UBX) was provided by Wedbush, and Unity Biotechnology upgraded their outperform rating.
When is the next analyst rating going to be posted or updated for Unity Biotechnology (UBX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unity Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unity Biotechnology was filed on November 16, 2023 so you should expect the next rating to be made available sometime around November 16, 2024.
Is the Analyst Rating Unity Biotechnology (UBX) correct?
While ratings are subjective and will change, the latest Unity Biotechnology (UBX) rating was a upgraded with a price target of $0.00 to $0.00. The current price Unity Biotechnology (UBX) is trading at is $1.94, which is out of the analyst's predicted range.
